Deadline: 16-Dec-22
The Grand Challenges in Global Health (GCGH) is inviting applications for the Pathogen Genomic Surveillance and Immunology in Asia.
The Challenge
- In response to this request for proposals, they seek projects from investigators in South and Southeast Asia that address one or both of the following two goals:
- Asia Pathogen Genomics Initiative (Asia PGI): Design and pilot a genomic surveillance program for a priority pathogen (other than SARS-CoV-2)
- Global Immunology and Immune Sequencing for Epidemic Response (GIISER) – Asia: Develop capacity for immune characterization of SARS-CoV-2 variants to inform Epidemic Response
- Across both goals, training of local scientists by collaborators willing and able to share knowledge and tools will create the necessary capabilities. A long-term goal is to establish a sustainable, local infrastructure that can be activated to respond to any new emerging pathogen locally and strengthen connections and collaborations between sites and with international decision-making bodies.
- Asia Pathogen Genomics Initiative (Asia PGI)
- Proposals are invited from country National Public Health Institutions (NPHIs) or public laboratories with links to the public health system.1 NPHI or lab staff may propose to develop a plan for genomic surveillance of priority pathogens or syndromes and to execute a pilot surveillance program.
- Specifically, they seek proposals from NPHIs or public labs to dedicate staff to developing a pathogen genomic surveillance program by spending 2 years working on the identified objectives. This may include collaboration or placement with an expert for 1-3 months to gain training and expertise. It is the proposing organization’s responsibility to identify collaborators or training institutes as needed.
- The objectives for Asia PGI are:
- To establish routine pathogen genomic surveillance to understand the epidemiology and transmission of a priority pathogen (other than SARS-CoV-2)
- To use pathogen genomics in the public health response – including field epidemiology response – to investigate potential evolution of a priority pathogen and its impact on the epidemiology of disease
- To use pathogen genomics to monitor the impact of vaccine introduction on the transmission dynamics or AMR characteristics of pathogen lineages causing disease.
- To use pathogen genomics to inform the development of diagnostics and/or therapeutics.
- Global Immunology and Immune Sequencing for Epidemic Response (GIISER) – Asia
- They invite proposals to increase the in-country capacity for rapid immunological evaluation of SARS-CoV-2 variants in South and Southeast Asia.
- A successful GIISER site will be able to systematically produce data quantifying immune escape and cross protection for variants of local concern/interest. This will require that sites are able to leverage existing pathogen sequencing surveillance infrastructure to rapidly identify emerging SARS-CoV-2 variants, use existing clinical cohorts to obtain sera and blood cells from relevantly infected individuals with appropriate informed consent, and perform detailed immunological characterization of sera/plasma (binding and neutralization assays), as well as single cell analytics for monoclonal antibody discovery.
- Specifically, they seek proposals from NPHIs or their academic partners to:
- Identify SARS-CoV-2 pathogen variants and appropriate subjects;
- Perform sample collection, virus isolation, and B cell sorting;
- Assess natural-infection-induced and vaccine-induced polyclonal antibody immunity to novel variants; and
- Discover monoclonal antibodies in appropriate subjects. By the end of the first year of a two-year investment, sites should be performing all necessary binding and neutralization assays in their lab and sharing those results.
- The objectives for GIISER-Asia are:
- Identify SARS-CoV-2 pathogen variants and appropriate subjects
- Sample Collection and Virus Isolation
- Assessment of natural-infection-induced and vaccine-induced polyclonal antibody immunity to novel variants
- Local monoclonal antibody discovery
- Local monoclonal antibody screening
- Develop capacity for immunological evaluation of SARS-CoV-2 variants of concern (and potentially other additional pathogens of global health importance) through project immersion and targeted training with partners
- Sustain and further develop expertise in virology, immunology, and communication with policy makers.
Funding Information
- Up to 300,000 USD per year for each project, with a grant term of up to 2 years depending on the scope of the project. An additional 300,000 USD may be added to the second year budget if a proposed project includes monoclonal antibody discovery activities.
Eligibility Criteria
- Asia PGI requirements: A successful Asia PGI site will formalize a framework to identify a priority pathogen or syndrome for genomic surveillance, build on the experience of sourcing samples for SARS-CoV-2 genomic surveillance and on the genomic sequencing skills gained during the pandemic, and access the expertise of epidemiologists and clinicians with insight into the epidemiology of the chosen pathogen or syndrome. They will prioritize funding for public labs or institutes that provide surveillance data to the government to inform public health interventions. Proposals should mention other available funding for the proposed work. Pathogens that are not covered by other funding mechanisms including large international programs will be prioritized. They also encourage applicants to describe the impact of ongoing, related work at the organization/site.
- All Asia PGI proposals must:
- Describe the framework used to prioritize the chosen pathogen or syndrome
- Describe in brief the SARS-CoV-2 genomic surveillance system in place
- Describe how staff can immediately put to use pathogen genomic sequencing technology at your site to respond to at least one of the Asia PGI objectives listed .
- Describe how skills will be developed in sequencing of the priority pathogen chosen
- Describe the sampling approach for obtaining specimens for genomic sequencing and how the sampling approach will be optimized to answer at least one of the objectives outlined . In addition, describe how metadata and clinical, epidemiological, or other data will be collected and combined with the sequencing data.
- Describe how the data generated from your project will be used to inform public health decision making in your area, country and/or region in a timely manner. How will you communicate your findings and engage with stakeholders to ensure uptake and use of your findings for these public health purposes? They expect that PGS data will be shared immediately with local government health officials as well as uploaded to a standard repository for genetic data such as GISAID, NCBI, or ENA.
- Articulate how the capacity built through the proposed project will strengthen your institute’s approach to using pathogen genomics for surveillance.
- GIISER-Asia requirements: A successful GIISER site will have access to existing pathogen sequencing capacity and bioinformatics, access to existing cohorts or clinical infrastructure, access to existing BLS3 labs and trained virologists and immunologists with some expertise in protein reagent generation. Not every site will have everything in place, but enthusiastic, creative and collaborative groups who want to get things done are encouraged to include specific requests for the support they need to get there (training, connections, technology, etc.)
- All GIISER-Asia proposals must:
- Describe the site’s ability to link together pathogen sequencing, clinical epidemiology, and immunology to rapidly produce high-quality, interpretable and informative data on neutralization breadth and cross protection for locally identified SARS-CoV-2 variants of concern.
- This includes, but is not limited to, outgrowth of variant SARS-CoV-2 virus in appropriate BLS3 containment labs for live virus neutralization assays. Examples of anticipated results: Cele et al Nature 2021, Moyo-Gwete et al NEJM 2021, Shen et al NEJM 2021 and Wibmer et al Nature Medicine 2021.
- Describe how, within the first year of the grant, the GIISER site will bring all required binding and neutralization assays into their lab and communicate their results.
- Describe how, within the second year of the grant, the GIISER site will be communicating results within 1-2 months of identifying a variant of local concern.
- Describe how, within the second year of the grant, the GIISER site will bring in all required capabilities for monoclonal antibody discovery and screening. (Proposals without an antibody scope will still be eligible for funding under this call.)
- Describe how the site will leverage existing local expertise, collaborate, and share data effectively with other GIISER sites and international networks
Ineligible
- Sequencing of extant samples or isolates will not be considered as responsive to this RFP. The proposal must include a plan for prospective genomic surveillance rather than simply genomic sequencing of existing samples.
- Funding of genomic surveillance in a setting with no experience with SARS-CoV-2 surveillance. The proposed studies must leverage equipment and/or human resource capacity that was instituted during the COVID-19 pandemic.
- GIISER-Asia sites that do not have funded pathogen genomics surveillance and existing clinical cohorts to build on for the immune characterization studies.
- Studies focused on T cell immunity and characterizing the overall immune response to SARS-CoV-2 are out of scope.
For more information, visit https://gcgh.grandchallenges.org/challenge/pathogen-genomic-surveillance-and-immunology-asia
